Pharmacokinetics of meloxicam in mature swine after intravenous andoral administration by Pairis-Garcia, Monique D. et al.
Animal Science Publications Animal Science
6-2015
Pharmacokinetics of meloxicam in mature swine
after intravenous andoral administration
Monique D. Pairis-Garcia
Iowa State University
Anna Johnson
Iowa State University, johnsona@iastate.edu
Butch Kukanich
Kansas State University
Larry W. Wulf
Iowa State University, spuds@iastate.edu
Suzanne T. Millman
Iowa State University, smillman@iastate.edu
See next page for additional authorsFollow this and additional works at: http://lib.dr.iastate.edu/ans_pubs
Part of the Agriculture Commons, Meat Science Commons, and the Pharmacy and
Pharmaceutical Sciences Commons
The complete bibliographic information for this item can be found at http://lib.dr.iastate.edu/
ans_pubs/113. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html.
This Article is brought to you for free and open access by the Animal Science at Digital Repository @ Iowa State University. It has been accepted for
inclusion in Animal Science Publications by an authorized administrator of Digital Repository @ Iowa State University. For more information, please
contact digirep@iastate.edu.
Authors
Monique D. Pairis-Garcia, Anna Johnson, Butch Kukanich, Larry W. Wulf, Suzanne T. Millman, Kenneth J.
Stalder, Locke A. Karriker, and Johann F. Coetzee
This article is available at Digital Repository @ Iowa State University: http://lib.dr.iastate.edu/ans_pubs/113
1 
Pharmacokinetics of meloxicam in mature swine after intravenous and oral administration 1 
Running title: Pharmacokinetics of meloxicam in mature swine 2 
Monique D. Pairis-Garcia1, Anna K. Johnson1, Butch Kukanich2, Larry Wulf3, Suzanne T, 3 
Millman4, Kenneth J. Stalder1, and Locke A. Karriker5 Johann F. Coetzee3,4* 4 
 5 
1 Department of Animal Science, Iowa State University, Ames, IA 50011, USA 6 
2 Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State 7 
University, Manhattan, KS 66506, USA  8 
3 Pharmacology Analytical Support Team (PhAST), College of Veterinary Medicine, Iowa State 9 
University, Ames, IA 50011, USA 10 
4 Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, IA 11 
50011, USA 12 
5 Swine Medicine Education Center, College of Veterinary Medicine, Iowa State University, 13 
Ames, IA 50011, USA 14 
*Corresponding author. Johann F. Coetzee. Email: hcoetzee@iastate.edu Phone: 515-294-7424, 15 
Fax number: 515-294-1072 16 
17 
18 
This is a manuscript of an article from  Journal of Veterinary Pharmacology and Therapeutics 38 (2015): 265, doi:10.11 11/jvp.12170. Posted with permission.
2 
 
Abbreviations 19 
AUC extrap, Percent of the AUC extrapolated; AUCINF, Area under the curve extrapolated to 20 
infinity; Cl, Plasma clearance; Cl/F, Cl per fraction of the dose absorbed; C0, Concentration 21 
extrapolated to time 0 using log-linear regression of the first two time points; CMAX, Maximum 22 
plasma concentration; TMAX, Time to CMAX; T ½ λz, Terminal half-life; λz, Terminal rate 23 
constant; MRT, Mean residence time extrapolated to infinity; Vss, Volume of distribution at 24 
steady state; Vz, Volume of distribution, area method; Vz/F, Vz per fraction of the dose 25 
absorbed; MAT, Mean absorption time; F, Fraction of the dose absorbed; COX, Cyclo-26 
oxygenase; HPLC-MS, High pressure liquid chromatography and mass spectrometry detection; 27 
PK, Pharmacokinetic; NSAIDS, Non-steroidal anti-inflammatory drugs; IV, Intravenous; IM, 28 
Intramuscular; PO, Per os (by mouth) 29 
 30 
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Abstract 38 
The purpose of this study was to compare the pharmacokinetics of meloxicam in mature swine 39 
after intravenous (IV) and oral (PO) administration. Six mature sows (mean bodyweight ± standard 40 
deviation = 217.3± 65.68 kg) were administered an IV or PO dose of meloxicam at a target dose 41 
of 0.5 mg/kg in a cross-over design. Plasma samples collected up to 48 hours post-administration 42 
were analyzed by high pressure liquid chromatography and mass spectrometry (HPLC-MS) 43 
followed by non-compartmental pharmacokinetic analysis. Mean peak plasma concentration 44 
(CMAX) after PO administration was 1070 ng/ml (645-1749 ng/ml). TMAX was recorded at 2.40 45 
hour (0.50-12.00 hours) after PO administration. Half-life (T ½ λz) for IV and PO administration 46 
was 6.15 hours (4.39-7.79 hours) and 6.83 hours (5.18-9.63 hours) respectively. The 47 
bioavailability (F) for PO administration was 87% (39-351%). The results of the present study 48 
suggest that meloxicam is well absorbed after oral administration. 49 
Keywords 50 
Swine, meloxicam, pharmacokinetics, NSAIDs, oral bioavailability, pig 51 
Introduction 52 
Over the past decade there has been increased awareness from the public on issues related 53 
to farm animal welfare. More specifically, concern over procedures that inflict pain upon pigs (i.e. 54 
castration, tail docking) and lack of pain relief available during these procedures has been 55 
highlighted as major concerns from the public (Guatteo et al., 2012; Coetzee, 2013a; Millman, 56 
2013). Non-steroidal anti-inflammatory drugs (NSAIDs) including ketoprofen, carprofen, flunixin 57 
meglumine and meloxicam are common analgesics used to manage animal pain and are labeled 58 
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for pain control for livestock in Canada and some European Union countries (Coetzee, 2013b). 59 
However there are currently no drugs approved for use in swine and specifically labelled to provide 60 
pain relief in the United States (FDA 2010). 61 
Meloxicam is a member of the oxicam class with anti-inflammatory, analgesic and antipyretic 62 
properties (Friton et al., 2003; Hirsch et al., 2003). Meloxicam is highly protein bound (95-99%), 63 
demonstrates good systemic absorption (Busch et al,. 1998) and may be a good candidate for pain 64 
mitigation in swine. To identify the optimal dose regimen for pain management, the 65 
pharmacokinetics of a drug must be determined. Pharmacokinetic (PK) parameters for meloxicam 66 
have been evaluated in several species including cattle (Coetzee et al., 2009; Mosher et al., 2012; 67 
Malreddy et al., 2013), small ruminants (Shukla et al., 2007; Ingvast-Larsson et al., 2010; Wasfi 68 
et al., 2012; Krueder et al., 2012; Stock et al., 2013), horses (Toutain et al., 2004; Sinclair et al., 69 
2006), exotics (Divers et al., 2010) and companion animals (Lees et al., 2013; Lehr et al., 2010). 70 
There have been two peer-reviewed articles published on Meloxicam PK in swine (Fosse et al., 71 
2008; 2010). However, these studies evaluated meloxicam PK properties in pre-pubertal swine age 72 
14-23 days and neither study evaluated oral bioavailability (F) of meloxicam. The purpose of this 73 
study was to compare the pharmacokinetic parameters of IV and oral meloxicam PK in mature 74 
swine and to determine the oral bioavailability. 75 
Methods 76 
This study was approved by the Institutional Animal Care and Use Committee at Iowa 77 
State University. 78 
 79 
Animals and housing 80 
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Six healthy multiparous commercial cross-bred Newsham cull sows (mean bodyweight ± 81 
standard deviation = 217.3± 65.68 kg) were used for this study. Sows were housed in individual 82 
pens with a concrete floor with and rubber mat (2.4 m length x 2 cm height x 1.4 m width). Sows 83 
were provided ad libitum access to water via one nipple drinker (Trojan Specialty Products Model 84 
65, Dodge City, KS) and hand-fed a custom mixed diet free of antibiotics or medications composed 85 
of corn, soybean meal and soy hulls, designed to meet or exceed nutrient requirements for sows. 86 
Approximately 1.8 kg of feed was fed at 0800 and 0.45 kg of feed was fed at 1600 hours onto a 87 
raised concrete step (55 cm length x 55 cm in width x 24 cm). Matrix (Altrenogest formulation; 88 
Intervet/Schering-Plough, Milsboro, DE- Dose: 6.8 ml-15 mg) was added to one kg of feed daily 89 
to prevent estrus cycle initiation.  90 
Twenty-four hours before study commencement, sows were moved to individual gestation 91 
stalls (2.1 m length x 0.6 m width) with nonslip rubber flooring. Sows had access to the same type 92 
of nipple drinker previously described for the pen, and remained in their stalls for a total of 72 93 
hours while on trial (on trial defined as sows receiving drug and having blood collected). Sows on 94 
trial, regardless of administration route, received the same ration and were fed on the same 95 
schedule as follows: Day 1: 0.9 kg at 5:00 (three and half hours prior to oral drug administration), 96 
1.4 kg at 12:30 and .45 kg at 17:00; Day 2: 2.3 kg at 8:30 and 0.45 kg at 17:00. Lights were on a 97 
12:12 light dark cycle (light hours [0600 and 1800]). Feed schedule was different on trial days due 98 
to trial schedule and blood collection time-points. Attitude, appetite, and blood collection sites of 99 
sows were monitored twice daily during each study period. Sows were assessed for immediate 100 
adverse reactions to drug administration including demonstrating signs of sedation, seizures, 101 
vomiting, diarrhea or respiratory compromise. Post-mortem necropsies were not conducted and 102 
clinical signs of melena were not evaluated.  103 
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Study design  104 
A cross-over design study (Navidi, 2008) was conducted over two rounds such that all 105 
sows received each administrative route. Sows were blocked by body weight and treatments were 106 
randomly assigned to sows within a block (three sows per block) with three sows allocated to each 107 
administration route for the first round. A10-day washout period was chosen as it was greater than 108 
89 times the half-life reported in swine (Fosse et al., 2008; T1/2 b : 2.7 hours). Sows were weighed 109 
20 hours prior to study initiation and these weights were used to calculate drug dosages.  110 
In the first round, three sows were administered an intravenous injection of meloxicam 111 
(IV-M) at 0.5 mg/kg (Loxicam 5 mg/ml; Norbrook Pharmaceuticals Worldwide, Station Works, 112 
Newry, Ireland # 1155103) as a single bolus injection into an indwelling auricular vein catheter 113 
using techniques described by Pairis-Garcia and colleagues (2014). Three sows received 114 
meloxicam per os (PO-M) at 0.5 mg/kg (Meloxicam 15 mg/tablet; Zydus Pharmaceuticals USA 115 
Inc, Pennington, New Jersey #MM5058). Tablets were mixed with approximately 24 g of sugar 116 
cookie dough (sows had been previously trained using cookie dough as a positive reinforcement), 117 
divided into three, 8 gram round balls, and administered in a clean feeding bowl. In the second 118 
round, this process was repeated so that all sows received both meloxicam routes. For oral 119 
administration, the dose was rounded to the nearest whole tablet. For intravenous administration, 120 
the dose was rounded to the nearest half milliliter. The experimental unit was the individual sow 121 
(n = 6/treatment).  122 
Blood collection  123 
All blood samples (9.0 mL/sample) were collected via the jugular vein using a 25.4 mm 16 124 
gauge hypodermic needle (Air-Tite Products, Virginia Beach, VA, USA) and 12 ml luer lock 125 
syringe (TycoHealth Care, Mansfield, MA, USA). During blood collection, sows were manually 126 
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restrained using a pig snare. Blood was collected from sows receiving IV-M at 0.05, 0.1, 0.17, 127 
0.33, 0.5, 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours after drug administration. Blood was collected 128 
from sows receiving PO-M at 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, 36, and 48 hours after PO 129 
administration. A baseline sample was collected 20 hours prior to drug administration for both 130 
routes. Samples were immediately transferred to a sodium heparin 10 ml blood collection tube 131 
(BD Vacutainer, Franklin Lakes, NJ, USA) and remained on ice for no longer than 150 minutes 132 
prior to centrifugation for 10 minutes at 1,500 g. Collected plasma was placed in cryovials and 133 
frozen at -70 °C until analysis. 134 
HPLC/MS analysis of meloxicam concentrations 135 
Plasma meloxicam concentrations were determined using high-pressure liquid chromatography 136 
(Surveyor MS Pump and Autosampler, Thermo Scientific, San Jose, CA, USA) with mass 137 
spectrometry (TSQ Quantum Discovery MAX, Thermo Scientific, San Jose, CA, USA). Plasma 138 
samples, spikes (0.20 ml) and the internal standard (piroxicam; 10 μL 40ng/ml) were treated with 139 
20 μL of 30% perchloric acid. Samples were vortexed for 5 seconds and centrifuged for 20 140 
minutes at 2,500 x g to precipitate the sediment. The supernatant (~80 μL) was pipetted into a 141 
glass insert containing 120 μL of 1.9% ammonium hydroxide in 25% aqueous acetonitrile and 142 
fitted to an injection vial. The injection volume equaled 12.5 μL. Two mobile phases utilized 143 
were as follows: A. 0.1% formic acid in water B. 0.1% formic acid in an acetonitrile at a flow 144 
rate of 0.250 mL/min. The mobile phase began at 15% B with a linear gradient to 95% B at 7 145 
minutes, which was maintained for 1.5 minutes, followed by a re-equilibration to 15% B. 146 
Separation was achieved with a solid-core c18 column (KinetexXB -C18, 100 mm×2.1 mm, 2.6 147 
μm particles, Phenomenex, Torrance, CA, USA)  maintained at 40°C. Piroxicam eluted at 4.85 148 
minutes and meloxicam at 5.95 minutes. Four SRM transitions were monitored for meloxicam 149 
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and three SRM transitions were used with the internal standard, piroxicam. The quantifying ions 150 
for meloxicam were 72.99, 88.01, 114.99, and 140.98 m/z and 77.97, 94.98, and 120.98 m/z for 151 
piroxicam. Sequences consisting of plasma blanks, calibration spikes, QC samples, and swine 152 
plasma samples were batch processed with a processing method developed in the Xcalibur 153 
software (Thermo Scientific, San Jose, CA, USA). The processing method automatically 154 
identified and integrated each peak in each sample and calculated the calibration curve based on 155 
a weighted (1/X) linear fit. Plasma concentrations of meloxicam in unknown samples were 156 
calculated by the Xcalibur software based on the calibration curve. Results were then viewed in 157 
the Quan Browser portion of the Xcalibur software. The standard curve in swine plasma was 158 
linear from 0.005 to 10.0 μg/mL. The coefficient of determination (R squared) exceeded 0.995 159 
and all measured values were within 15% of the actual values with most of the values less than 160 
5% difference from the actual values. The accuracy of the assay for meloxicam in swine plasma 161 
was 99 ± 3% of the actual concentration while the coefficient of variation was 5% determined on 162 
4 sets of replicates for each of the following concentrations: 0.015, 0.15, and 1.5 μg/mL. The 163 
limit of quantitation (LOQ) for this assay was determined to be 0.005 ug/mL, while the limit of 164 
detection (LOD) was 10-fold lower than that at 0.0005 ug/mL. 165 
Pharmacokinetic analysis 166 
Pharmacokinetic analyses for plasma meloxicam concentrations over time were performed 167 
with computer software (WinNonlin 5.2, Pharsight Corporation, Mountain View, CA, USA) and 168 
analyzed using non-compartmental methods (Gibaldi and Perrier, 1982).The parameters included 169 
the area under the curve from time 0 to infinity (AUCINF) using the linear trapezoidal rule, percent 170 
of the AUC extrapolated to infinity (AUC EXTRAP), plasma clearance (Cl), first-order rate constant 171 
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(λz), terminal half-life (T½ λz), apparent volume of distribution at steady state (Vss), apparent 172 
volume of distribution of the area (Vz), mean residence time extrapolated to infinity (MRT), and 173 
mean absorption time (MAT). The maximum plasma concentration (CMAX) and the time to 174 
maximum plasma concentration (TMAX) were observed for PO administration. The concentration 175 
at time 0 (C0) was calculated by log-linear regression using the first two time points after IV 176 
administration. The AUCEXTRAP was the percent of the AUC extrapolated to infinity. The range of 177 
the λz was determined by visual inspection of the plasma profile and determined by linear 178 
regression of time and natural log (ln) of the plasma concentration. The Vz was determined using 179 
the following equation: 180 
ܸݖ ൌ 	 ܦ݋ݏ݁ߣݖ ∗ ܣܷܥூேி 181 
The Vss was determined with the following equation: 182 
ܸݏݏ ൌ ܯܴܶ ∗ ܥ݈ 183 
 184 
The F was estimated with the following equation: 185 
ܨ ൌ
ܣܷܥ	ሺܱܲ െܯሻ
ܦ݋ݏ݁	ሺܱܲ െܯሻ
ܣܷܥ	ሺܫܸ െ ܯሻ
ܦ݋ݏ݁	ሺܫܸ െ ܯሻ
 186 
 187 
The MAT with the following equation: 188 
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ܯܣܶ ൌ ܯܴܶ	ሺܱܲ െܯሻ െܯܴܶ	ሺܫܸ െ ܯሻ 189 
Given that pharmacokinetic parameters data follow a log-normal distribution, geometric statistics 190 
are more appropriate summary descriptors and have been presented in this study. 191 
 192 
Results 193 
No adverse effects (sedation, seizures, vomiting, diarrhea, or respiratory compromise) from the 194 
sow were observed following IV or PO meloxicam administration and drug levels were below the 195 
limit of detection on baseline days. Two samples were excluded for IV administration at the 24 196 
hour time point due to unclear labeling with unclear sow identification. Two samples were 197 
excluded for IV administration and PO administration at the 48 hour time point as samples were 198 
below LOQ. A 13.9% variation within samples was detected as compared to the internal standard 199 
response across all samples.  200 
Figure 1 and 2 presents the individual plasma profiles for IV-M and PO-M administered at 0.5 201 
mg/kg (actual mean dose: IV: 0.50 mg/kg; range: 0.49-0.50 mg/kg; PO: 0.49 mg/kg; range 0.47-202 
0.51 mg/kg).  203 
Table 1 summarizes the calculated PK for IV-M and Table 2 summarizes the calculated PK for 204 
PO-M.  205 
Discussion 206 
In this study, we compared the PK parameters of IV and PO meloxicam in mature swine 207 
and determined the oral bioavailability. Although meloxicam PK properties were previously 208 
evaluated at 0.4 mg/kg in swine (Fosse et al., 2008; 2010), the authors completed this work using 209 
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younger, immature pigs (14-23 days of age) and did not evaluate PO-M administration. Hence, 210 
the present study is novel because we determined these parameters, including oral, in mature pigs 211 
using a different route of administration and dose. . 212 
The MRT of 4.26 hour and Cmax at 5705 ng/ml were numerically greater than results 213 
reported by Fosse and colleagues, 2008 (MRT: 3.5 ± 0.3 h; Cmax: 3277 ± 250 ng/ml) although 214 
Vss was similar at 0.16 l/kg (Fosse et al 2008; Vss: 0.19± 0.02 l/kg) and the Cl was slower at 215 
0.63 ml/min/kg (Fosse et al 2008; Cl: 1.01 mL/kg/min). Half-life was also different when 216 
compared to previous results from Fosse and colleagues (2010; T ½ λz 2.6h), Norbrook 217 
Laboratories (2014; T ½ λz 2.5h) and laboratory pigs (T ½ λz 2.48h; European Agency for the 218 
Evaluation of Medicinal Products (EMA), 1999), although similar to results for mice and mini-219 
pigs (EMA, 1999; T ½ λz 4-6h). Although the cause of these differences is unknown, several 220 
factors may have contributed to the numerical differences. Since these were separate studies, 221 
direct comparison should always be cautious as differences in study design such as routes of 222 
administration, fed or fasted animals, sample collection times, analytical method (including limit 223 
of quantification, sensitivity, and specificity), drug formulations, environmental factors and 224 
pharmacokinetic analyses differences could all contribute to some of the perceived differences. 225 
Differences in pharmacokinetic parameters from our study compared to previously published 226 
results may also be due to differences in age, genetics, weight or additional unknown differences 227 
between study populations. Although it is often assumed that young animals always have slower 228 
drug metabolism / elimination than adults, this is not the case. In Beagle dogs for example, 229 
puppies aged 5-20 weeks have shorter half-lives and more rapid clearance of caffeine than adult 230 
dogs (Tanaka et al., 1998). Similarly the half-life is shorter in puppies aged 3-30 weeks and the 231 
clearance is more rapid of trimethadione (a nonspecific metabolism substrate) than adult dogs 232 
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(Tanaka et al., 1998). Mosher and colleagues (2012) demonstrated differences in half-life when 233 
comparing pre-ruminant calves and ruminant calves administered meloxicam by gavage (pre-234 
ruminant calves dosed via gavage: T ½ λz 40.0h; ruminant claves dosed via gavage: T ½ λz 235 
29.9h). In addition, breed or strain differences may also contribute due to genetic differences 236 
(polymorphisms) in metabolism, but to the authors’ knowledge, genetic polymorphisms or 237 
extensive studies of the effects of age on drug metabolism in pigs have not been reported.  238 
Previous studies have demonstrated excellent bioavailability for meloxicam ranging 239 
between 72-100% F when administered to horses and ruminants (Calves: Coetzee et al., 2009; 240 
Goats: Ingvast-Larsson et al., 2010; Horses: Toutain et al., 2004; Sheep: Stock et al., 2013; 241 
Camels: Wasfi et al., 2012; Llamas: Krueder et al., 2012). Our study demonstrated oral F at 87% 242 
(range 39-350%). The lower range in F coincides with previous studies conducted in sheep 243 
(Stock et al, 2013; 40%) and llamas (Kreuder et al, 2012; 48%).  As there are no other studies 244 
assessing bioavailability in sows, it is unclear if variability in F should be expected in sows, or 245 
other factors such as feeding regimen or drug formulation influenced this outcome.  246 
When assessing the upper range of F at 350% a possible explanation for the elevated F 247 
from this particular sow may be due to slow absorption. As the drug was administered orally we 248 
can rule out slow absorption due to administration complications such as hemorrhage, injection 249 
into fascial plane or seroma formation. However, drug absorption by oral administration can be 250 
influenced by local damage at the site of absorption (gastrointestinal tract), decreased blood flow 251 
and variation in stomach contents (Maddison et al, 2008). Gastric ulcers, intestinal torsions, 252 
volvulus and proliferative enteropathy are common problems seen in swine (Thomson and 253 
Friendship, 2012). Compromised gastric mucosa due to disease may result in decreased blood 254 
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flow to the affected site, prolonged retention of feed and decrease in total surface area resulting 255 
in potentially slower drug absorption (Page and Maddison, 2008). As sows enrolled on trial were 256 
purchased from a group of commercial cull sows, chronic gastrointestinal disease or compromise 257 
may be possible. Necropsies of sows were not performed therefore gastrointestinal tract status is 258 
unknown and may have played a role in variations seen with oral meloxicam F. Therefore, it may 259 
be more appropriate to use the median F at 69% or estimated F without this sow (67%) as a 260 
better indicator of true F.  261 
Conclusions 262 
The pharmacokinetic profile of oral meloxicam described in this study including the high relative 263 
bioavailability support clinical evaluation of this compound for management of pain in sows. 264 
Meloxicam may be both cost effective and require little additional training for administration on 265 
farm.  266 
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